Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 3/20 | 0.35 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.35 |
| ▸ | BLM | P54132 | 3/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.32 |
| ▸ | GSR | P00390 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2148512 | 0.95 | GABBR2 (0.36) | GABBR2GABBR1BLMDRD3CYP1A2 | |
| SCHEMBL2148324 | 0.88 | GABBR2 (0.42) | GABBR2GABBR1BLMDRD3CYP1A2 | |
| SCHEMBL2148327 | 0.77 | BLM (0.41) | GABBR2GABBR1BLMDRD3CYP1A2 | |
| SCHEMBL2148514 | 0.76 | PAOX (0.40) | GABBR2GABBR1BLMDRD3CYP1A2 | |
| SCHEMBL2148490 | 0.76 | PAOX (0.40) | GABBR2GABBR1BLMDRD3CYP1A2 | |
| SCHEMBL9564515 | 0.75 | BLM (0.46) | GABBR2GABBR1BLMDRD3CYP1A2 | |
| SCHEMBL9796748 | 0.73 | NFKB1 (0.39) | BLMTSHRLMNAGSRNFKB1 | |
| SCHEMBL2148429 | 0.72 | ANPEP (0.39) | ALDH1A1TDP1 | |
| SCHEMBL2148523 | 0.71 | ANPEP (0.38) | GABBR2GABBR1BLMDRD3CYP1A2 | |
| SCHEMBL2148521 | 0.70 | LAP3 (0.36) | ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130090312-A1 | METHODS OF USE RELATED TO XEROSTOMIA | MEDIMMUNE LLC (US) | 2013-04-11 | — | — | US | disclosed |
| US-20110166108-A1 | METHODS OF USE RELATED TO XEROSTOMIA | MEDIMMUNE, LLC. | 2011-07-07 | — | — | US | disclosed |
| US-7629333-B2 | Stable amorphous amifostine compositions and methods for the preparation and use of same | MEDIMMUNE, LLC (US) | 2009-12-08 | — | — | US | disclosed |
| US-20080027030-A1 | Pharmaceutical compositions comprising amifostine and related compounds | STOGNIEW MARTIN | 2008-01-31 | — | — | US | disclosed |
| EP-1764103-A2 | Crystalline amifostine compositions and methods for the preparation and use of same | Medimmune Oncology, Inc. (US) | 2007-03-21 | — | — | EP | disclosed |
| US-7151094-B2 | Topical administration of amifostine and related compounds | MEDLMMUNE ONCOLOGY, INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-20060270636-A1 | Methods for treatment of neuro- and nephro- disorders and therapeutic toxicities using aminothiol compounds | MEDIMMUNE ONCOLOGY, INC. | 2006-11-30 | — | — | US | disclosed |
| US-7105575-B2 | Methods for the treatment of neuro- disorders using aminothiol compounds | MEDIMMUNE ONCOLOGY INC. (US) | 2006-09-12 | — | — | US | disclosed |
| EP-1039887-B1 | USE OF AMINOTHIOL COMPOUNDS FOR THE TREATMENT OF NEURO- AND NEPHRO-DISORDERS AND THERAPEUTIC TOXICITIES | MEDIMMUNE ONCOLOGY INC (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060040903-A1 | Methods of use related to xerostomia | STOGNIEW MARTIN | 2006-02-23 | — | — | US | disclosed |
| US-20020010357-A1 | STABLE AMORPHOUS AMIFOSTINE COMPOSITIONS AND DOSAGE FORM | CLINIGEN GROUP PLC (GB) | 2002-01-24 | — | — | US | disclosed |
| US-6239119-B1 | PROTECTING MUCOSAL TISSUE FROM DAMAGE ASSOCIATED WITH RADIATION AND/OR CHEMOTHERAPEUTIC TREATMENT OF CANCERS, AVOID THE SIDE EFFECTS OF SYSTEMICALLY APPLIED RADIO/CHEMO PROTECTANTS. | MEDIMMUNE ONCOLOGY, INC. | 2001-05-29 | — | — | US | disclosed |
| EP-1039887-A1 | METHODS FOR TREATMENT OF NEURO- AND NEPHRO-DISORDERS AND THERAPEUTIC TOXICITIES USING AMINOTHIOL COMPOUNDS | U.S. BIOSCIENCE, INC. (US) | 2000-10-04 | — | — | EP | disclosed |
| US-5994409-A | Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds | U.S. BIOSCIENCE, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| WO-1999029312-A1 | METHODS FOR TREATMENT OF NEURO- AND NEPHRO-DISORDERS AND THERAPEUTIC TOXICITIES USING AMINOTHIOL COMPOUNDS | U.S. BIOSCIENCE, INC. (US) | 1999-06-17 | — | — | WO | disclosed |
| US-5591731-A | Crystalline amifostine compositions | U.S. BIOSCIENCE, INC. (US) | 1997-01-07 | — | — | US | disclosed |
| EP-0655917-A4 | CRYSTALLINE AMIFOSTINE COMPOSITIONS AND METHODS FOR THE PREPARATION AND USE OF SAME. | US BIOSCIENCE (US) | 1995-08-02 | — | — | EP | disclosed |
| US-5424471-A | Stabilizing the drug for storage stability, heat resistance by hydrating in an alcohol water solution, vacuum drying to form solid crystals | U.S. BIOSCIENCE, INC. (US) | 1995-06-13 | — | — | US | disclosed |
| EP-0655917-A1 | CRYSTALLINE AMIFOSTINE COMPOSITIONS AND METHODS FOR THE PREPARATION AND USE OF SAME | U.S. BIOSCIENCE, INC. (US) | 1995-06-07 | — | — | EP | disclosed |
| WO-1994003179-A1 | CRYSTALLINE AMIFOSTINE COMPOSITIONS AND METHODS FOR THE PREPARATION AND USE OF SAME | U.S. BIOSCIENCE, INC. (US) | 1994-02-17 | — | — | WO | disclosed |